Treatment of catastrophic antiphospholipid syndrome

Current Opinion in Rheumatology

Volumn 28, Issue 3, 2016, Pages 218-227

  Kazzaz, Nayef M ^a   Joseph McCune, W ^a   Knight, Jason S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antiphospholipid syndrome; Catastrophic antiphospholipid syndrome; Lupus anticoagulant; Microangiopathic hemolytic anemia; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ECULIZUMAB; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; RITUXIMAB; GLUCOCORTICOID;

AIR CONDITIONING; ANTIBODY DETECTION; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING TIME; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; COLON CANCER; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ESCHERICHIA COLI INFECTION; GLYCEMIC CONTROL; HELLP SYNDROME; HEMATOLOGIC MALIGNANCY; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERFERRITINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE; KLEBSIELLA INFECTION; LUNG CANCER; MORTALITY; PATHOPHYSIOLOGY; PLASMAPHERESIS; PREGNANCY; PRIORITY JOURNAL; REVIEW; SALMONELLOSIS; SHIGELLOSIS; STAPHYLOCOCCUS INFECTION; STOMACH ULCER; STREPTOCOCCUS INFECTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; CATASTROPHIC ILLNESS; DISEASE MANAGEMENT; PLASMA EXCHANGE; PRACTICE GUIDELINE; PROCEDURES; RECURRENT DISEASE;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; CATASTROPHIC ILLNESS; DISEASE MANAGEMENT; GLUCOCORTICOIDS; HUMANS; PLASMA EXCHANGE; PRACTICE GUIDELINES AS TOPIC; RECURRENCE;

EID: 84959230141     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000269     Document Type: Review

References (67)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295-306
2. Abreu MM, Danowski A, Wahl DG, et al. The relevance of ''non-criteria'' clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015; 14:401-414
3. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46:1019-1027
4. Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014; 13:685-696
5. Cervera R, Font J, Gomez-Puerta JA, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 2005; 64:1205-1209
6. Cervera R, Bucciarelli S, Plasin MA, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the 'CAPS Registry'. J Autoimmun 2009; 32:240-245
7. Cervera R, Rodriguez-Pinto I, Colafrancesco S, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on catastrophic antiphospholipid syndrome. Autoimmun Rev 2014; 13:699-707
8. Ortega-Hernandez OD, Agmon-Levin N, Blank M, et al. The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: compelling evidence. J Autoimmun 2009; 32:1-6
9. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368:1033-1044
10. Yalavarthi S, Gould TJ, Rao AN, et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol 2015; 67:2990-3003
11. Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (antibeta(2)-glycoprotein I) antibodies-effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001; 44:2870-2878
12. Pierangeli SS, Girardi G, Vega-Ostertag M, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52:2120-2124
13. Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106:2340-2346
14. Meroni PL, Ronda N, Angelis V, et al. Role of anti-beta2 glycoprotein I antibodies in antiphospholipid syndrome: in vitro and in vivo studies. Clin Rev Allergy Immunol 2007; 32:67-74
15. Kitchens CS. Thrombotic storm: when thrombosis begets thrombosis. Am J Med 1998; 104:381-385
16. D'Angelo A, Kluft C, Verheijen JH, et al. Fibrinolytic shut-down after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitor. Eur J Clin Invest 1985; 15:308-312
17. Espinosa G, Bucciarelli S, Cervera R, et al. Laboratory studies on pathophysiology of the catastrophic antiphospholipid syndrome. Autoimmun Rev 2006; 6:68-71
18. Dosekun AK, Pollak VE, Glas-Greenwalt P, et al. Ancrod in systemic lupus erythematosus with thrombosis. Clinical and fibrinolysis effects. Arch Intern Med 1984; 144:37-42
19. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992; 19:508-512
20. Asherson RA, Espinosa G, Cervera R, et al. Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment. J Clin Rheumatol 2002; 8:157-165
21. Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12:530-534
22. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7:1737-1740
23. Gebhart J, Posch F, Koder S, et al. Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). Blood 2015; 125:3477-3483
24. Isert M, Miesbach W, Stoever G, et al. Screening for lupus anticoagulants in patients treated with vitamin K antagonists. Int J Lab Hematol 2015; 37:758-765
25. Bertolaccini ML, Amengual O, Andreoli L, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014; 13:917-930
26. Martinuzzo ME, Barrera LH, Da MA, et al. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int J Lab Hematol 2014; 36:144-150
27. Wenzel C, Stoiser B, Locker GJ, et al. Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med 2002; 30:763-770
28. Vassalo J, Spector N, Meis E, et al. Antiphospholipid antibodies in critically ill patients with cancer: a prospective cohort study. J Crit Care 2014; 29:533-538
29. Rodriguez-Pinto I, Espinosa G, Cervera R. Catastrophic APS in the context of other thrombotic microangiopathies. Curr Rheumatol Rep 2015; 17:482
30. Agmon-Levin N, Rosario C, Katz BSP, et al. Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). Lupus 2013; 22:1327-1335
31. Montecucco C, Di Lauro M, Bobbio-Pallavicini E, et al. Antiphospholipid antibodies and thrombotic thrombocytopenic purpura. Clin Exp Rheumatol 1987; 5:355-358
32. Berman H, Rodriguez-Pinto I, Cervera R, et al. Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the ''CAPS Registry''. Autoimmun Rev 2014; 13:157-162
33. Damian L, Rednic S, Cristea A, et al. Viral-induced catastrophic antiphospholipid syndrome: two cases with favourable outcome. Ann Rheum Dis 2004; 63:330
34. Ku EW, Mizrachi A, Cohn J. Catastrophic antiphospholipid syndrome secondary to mycobacterium tuberculosis infection: a case report. Blood 2003; 102:107B
35. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001; 80:355-377
36. Bucciarelli S, Espinosa G, Cervera R. The CAPS Registry: morbidity and mortality of the catastrophic antiphospholipid syndrome. Lupus 2009; 18:905-912
37. Miesbach W, Asherson RA, Cervera R, et al. The role of malignancies in patients with catastrophic antiphospholipid (Asherson's) syndrome. Clin Rheumatol 2007; 26:2109-2114
38. Miesbach W, Asherson RA, Cervera R, et al. The catastrophic antiphospholipid (Asherson's) syndrome and malignancies. Autoimmun Rev 2006; 6:94-97
39. Gomez-Puerta JA, Cervera R, Espinosa G, et al. Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis 2007; 66:740-746
40. Hanouna G, Morel N, Le Thi Huong D, et al. Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases. Rheumatology (Oxford) 2013; 52:1635-1641
41. Bayraktar UD, Erkan D, Bucciarelli S, et al. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol 2007; 34:346-352
42. Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015; 74:1011-1018
43. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8:237-242
44. Ichikawa K, Koike T. Catastrophic antiphospholipid syndrome in Japanese population. Arthritis Rheum 2003; 48:S361
45. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome-clinical and laboratory features of 50 patients. Medicine 1998; 77:195-207
46. Bucciarelli S, Espinosa G, Cervera R, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006; 54:2568-2576
47. Erkan D, Asherson RA, Espinosa G, et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis 2003; 62:530-533
48. Bucciarelli S, Espinosa G, Asherson RA, et al. The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients. Ann Rheum Dis 2006; 65:81-86
49. Asherson RA. The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. Lupus 1998; 7 (Suppl. 2):S55-S62
50. Isenberg DA, Morrow WJ, Snaith ML. Methyl prednisolone pulse therapy in the treatment of systemic lupus erythematosus. Ann Rheum Dis 1982; 41:347-351
51. Uthman I, Shamseddine A, Taher A. The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome. Transfus Apher Sci 2005; 33:11-17
52. Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the 'CAPS Registry'. Semin Thromb Hemost 2012; 38:333-338
53. Branch DW, Peaceman AM, Druzin M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol 2000; 182:122-127
54. Sciascia S, Giachino O, Roccatello D. Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. Clin Exp Rheumatol 2012; 30:409-413
55. Shoenfeld Y, Katz U. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 2005; 38:123-137
56. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010; 47:115-123
57. Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol 2010; 29:707-716
58. Berman H, Rodriguez-Pinto I, Cervera R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2013; 12:1085-1090
59. Erkan D, Vega J, Ramon G, et al. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum 2013; 65:464-471
60. Chighizola CB, Favalli EG, Meroni PL. Novel mechanisms of action of the biologicals in rheumatic diseases. Clin Rev Allergy Immunol 2014; 47:6-16
61. Cofiell R, Kukreja A, Bedard K, et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 2015; 125:3253-3262
62. Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014; 14:459-465
63. Kronbichler A, Frank R, Kirschfink M, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore) 2014; 93:e143
64. Barratt-Due A, Floysand Y, Orrem HL, et al. Complement inhibition may be lifesaving in catastrophic antiphospholipid syndrome. Mol Immunol 2015; 67:122
65. Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 2012; 64:2719-2723
66. Zikos TA, Sokolove J, Ahuja N, Berube C. Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome. J Clin Rheumatol 2015; 21:311-313
67. Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev 2006; 6:98-103